In some embodiments, the pharmaceutical formulations or compositions described herein are stable with respect to compound degradation over a period of any of at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, at least about 7 weeks, at least about 8 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, or at least about 6 months
Amrita Datta, et al
- Leave on for 1015 minutes
Melanoma in Precancerous Melanosis|Malignant Cutaneous (Skin) Melanoma in Precancerous Melanosis|Malignant Melanoma in Precancerous Melanosis|Malignant melanoma in precancerous melanosis a benign congenital or acquired lesion that arises from mucosal sites and is characterized by melanin pigment deposition in the basilar keratinocytes
Protein purificationBirA (Uniprot PO6709 ) E
